1. Home
  2. SWTX vs MRX Comparison

SWTX vs MRX Comparison

Compare SWTX & MRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • MRX
  • Stock Information
  • Founded
  • SWTX 2017
  • MRX 2005
  • Country
  • SWTX United States
  • MRX United Kingdom
  • Employees
  • SWTX N/A
  • MRX N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • MRX
  • Sector
  • SWTX Health Care
  • MRX
  • Exchange
  • SWTX Nasdaq
  • MRX NYSE
  • Market Cap
  • SWTX 3.5B
  • MRX 2.5B
  • IPO Year
  • SWTX 2019
  • MRX 2024
  • Fundamental
  • Price
  • SWTX $46.26
  • MRX $47.38
  • Analyst Decision
  • SWTX Buy
  • MRX Strong Buy
  • Analyst Count
  • SWTX 7
  • MRX 8
  • Target Price
  • SWTX $56.86
  • MRX $35.25
  • AVG Volume (30 Days)
  • SWTX 8.7M
  • MRX 1.3M
  • Earning Date
  • SWTX 05-20-2025
  • MRX 05-15-2025
  • Dividend Yield
  • SWTX N/A
  • MRX 0.88%
  • EPS Growth
  • SWTX N/A
  • MRX 49.45
  • EPS
  • SWTX N/A
  • MRX 2.72
  • Revenue
  • SWTX $191,589,000.00
  • MRX $2,356,700,000.00
  • Revenue This Year
  • SWTX $86.36
  • MRX N/A
  • Revenue Next Year
  • SWTX $69.02
  • MRX $8.84
  • P/E Ratio
  • SWTX N/A
  • MRX $17.46
  • Revenue Growth
  • SWTX 3417.33
  • MRX 25.22
  • 52 Week Low
  • SWTX $28.21
  • MRX $18.13
  • 52 Week High
  • SWTX $62.00
  • MRX $48.91
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 58.93
  • MRX N/A
  • Support Level
  • SWTX $46.10
  • MRX N/A
  • Resistance Level
  • SWTX $46.27
  • MRX N/A
  • Average True Range (ATR)
  • SWTX 0.90
  • MRX 0.00
  • MACD
  • SWTX 0.58
  • MRX 0.00
  • Stochastic Oscillator
  • SWTX 99.46
  • MRX 0.00

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About MRX MAREX GROUP PLC

Marex Group PLC is a company that offers a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy, commodities and financial markets. It provides critical services to the clients by connecting them to global exchanges and providing a range of execution and hedging services across a range of its asset and products. They operate in a large and fragmented market with significant infrastructure requirements and regulatory and technological complexity, resulting in high barriers to entry.

Share on Social Networks: